Prime Therapeutics LLC

10/15/2026 | Press release | Distributed by Public on 10/15/2026 10:25

Prime’s managed care residency connects clinical expertise, pharmacy and medical benefits

Prime Therapeutics (Prime) is helping to prepare the next generation of managed care pharmacy leaders through its industry-leading postgraduate Year-1 (PGY1) residency program, accredited by the American Society of Health-System Pharmacists (ASHP). The program gives early-career pharmacists hands-on experience connecting medical and pharmacy benefits to support better outcomes for patients and health plans. Residents also build core managed care skills in utilization management, clinical operations, pricing and formulary development.

"Prime's residency program is truly a launchpad for the next generation of managed care pharmacy leaders," said YuQian Liu, PharmD, RPh, senior director of specialty clinical solutions and residency program director. "Residents gain the opportunity to drive meaningful change in patient outcomes and health plan performance. Prime's program blends hands-on experience with strategic clinical thinking, equipping pharmacists with the knowledge to navigate a rapidly evolving healthcare landscape."

Through practical rotations and collaboration with experts across Prime, residents gain experience in:

  • Medical and specialty drug management
  • Specialty clinical programs including oncology, hemophilia, rare disease and more
  • Utilization management and clinical reviews
  • Integrated medical and pharmacy benefit management
  • Health economics and outcomes research
  • Advanced Pharmacy Practice Experience student precepting
  • Presenting at various educational conferences

Learn more about the residency program

Register to learn more about Prime's residency program at 6 p.m. ET on Wednesday, Nov. 4. This 60-minute webinar will provide program overview, rotation structure, compensation and benefits, plus requirements to apply.

Register for the webinar at PrimeTherapeutics.com/Residency-Program.

Prime Therapeutics LLC published this content on October 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 16:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]